Physician profile
Jane Ko
NPI 1780892729
$3,598.91
in general payments reported to CMS, 2019-2025
29 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $410 · 2021: $488 · 2022: $541 · 2023: $619 · 2024: $489 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.07 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $482.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $398.22 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $295.69 | 2019-2022 | |
| Abbott Laboratories | $260.81 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $244.22 | 2021-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $215.03 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $148.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $133.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $116.08 | 2019-2025 | |
| Corcept Therapeutics | $105.26 | 2024-2025 | Korlym |
| Ascensia Diabetes Care US INC. | $82.54 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $80.37 | 2019-2020 | |
| Zealand Pharma US, INC. | $62.75 | 2021 | |
| Amarin Pharma, INC. | $49.71 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $43.61 | 2021-2024 | Recorlev |
| Esperion Therapeutics, INC. | $38.36 | 2020 | |
| Medtronic, INC. | $38.04 | 2023 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Vistapharm, INC. | $37.66 | 2021 | |
| Nevro Corp. | $33.99 | 2023 | Senza |
| Rgh Enterprises LLC | $27.86 | 2025 | |
| Valeritas, INC. | $27.09 | 2019 | |
| Tandem Diabetes Care, INC. | $26.10 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Gilead Sciences, INC. | $25.64 | 2019 | |
| Medtronic Minimed, INC. | $22.42 | 2020 | |
| Beta Bionics, INC. | $16.17 | 2023 | Ilet Bionic Pancreas |
| Ultragenyx Pharmaceutical INC. | $14.82 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2024 | |
| Lifescan, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.